Explore our materials

Filters

Results (5255)

Slideset

Tuberculosis

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

The relationship between pyrazinamide pharmacokinetics (PK) and microbiologic outcomes in patients with pulmonary TB receiving standard- or high-dose rifampicin: PK/PD results from TBTC trials 27 and 28 and PanACEA MAMS | K. Dooley

Slideset

Tuberculosis

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Application Of A Multi-Compartment Permeability-Limited Lung Model To Predict Lung Concentrations Of Moxifloxacin In Virtual Human Subjects | O. Hatley

Slideset

Tuberculosis

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis. | I. Gardner

Slideset

Tuberculosis

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Lost in translation: learning from preclinical data | Gerry Davies

Slideset

Tuberculosis

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

A Need for altering Tuberculosis Dosing Regiments for patients with HIV-associated Tuberculous Meningitis | G. Aljayyoussi

Slideset

Tuberculosis

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Sub-therapeutic concentrations of anti-tuberculosis drugs in children when treated according to indian dosing recommendation | B. Guiastrennec

Slideset

Tuberculosis

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Early interventions for diabetes related tuberculosis hasten sputum microbiological clearance in Virginia, USA | S. Heysell

Charles Peloquin

PharmD

Slideset

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Charles Peloquin, PharmD

Slideset

Tuberculosis

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Lung Tissue Concentrations of Pyrazinamide among Patients with Tuberculosis | R. Kempker

Slideset

Viral Hepatitis and Liver Disease

Symposium on Key Issues in Liver Transplantation for NASH 2016

How should we optimize immunosuppression? - Kittie Wynne, MD, PhD

Slideset

Viral Hepatitis and Liver Disease

Symposium on Key Issues in Liver Transplantation for NASH 2016

What is an acceptable BMI - Lee Kaplan, MD, PhD

Slideset

Viral Hepatitis and Liver Disease

Symposium on Key Issues in Liver Transplantation for NASH 2016

Explore our materials

Your Selection Clear All

Topic

Material Type

The relationship between pyrazinamide pharmacokinetics (PK) and microbiologic outcomes in patients with pulmonary TB receiving standard- or high-dose rifampicin: PK/PD results from TBTC trials 27 and 28 and PanACEA MAMS | K. Dooley

Application Of A Multi-Compartment Permeability-Limited Lung Model To Predict Lung Concentrations Of Moxifloxacin In Virtual Human Subjects | O. Hatley

Development of a novel multi-compartment granuloma model to predict local drug distribution and its impact on pharmacodynamics and disease progression in tuberculosis. | I. Gardner

Lost in translation: learning from preclinical data | Gerry Davies

A Need for altering Tuberculosis Dosing Regiments for patients with HIV-associated Tuberculous Meningitis | G. Aljayyoussi

Sub-therapeutic concentrations of anti-tuberculosis drugs in children when treated according to indian dosing recommendation | B. Guiastrennec

Early interventions for diabetes related tuberculosis hasten sputum microbiological clearance in Virginia, USA | S. Heysell

Rifampin vs. Rifapentine: a debate over the preferred rifamycin | Charles Peloquin, PharmD

Lung Tissue Concentrations of Pyrazinamide among Patients with Tuberculosis | R. Kempker

How should we optimize immunosuppression? - Kittie Wynne, MD, PhD

What is an acceptable BMI - Lee Kaplan, MD, PhD

Can Bariatric surgery convert a non-candidate to a candidate? - Julie Heimbachx, MD